Get the Stockscreener App
7.48
1.06%
-0.08
Niagen Bioscience Inc stock is traded at $7.48, with a volume of 1.58M.
It is down -1.06% in the last 24 hours and down -22.08% over the past month.
Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.
See More
Previous Close:
$7.56
Open:
$7.48
24h Volume:
1.58M
Relative Volume:
1.39
Market Cap:
$596.55M
Revenue:
$116.30M
Net Income/Loss:
$17.73M
P/E Ratio:
35.62
EPS:
0.21
Net Cash Flow:
$20.88M
1W Performance:
+7.94%
1M Performance:
-22.08%
6M Performance:
+31.92%
1Y Performance:
+0.00%
1-Day Range:
$7.28
$7.69
1-Week Range:
$6.995
$7.70
52-Week Range:
$5.33
$14.69
Niagen Bioscience Inc Stock (NAGE) Company Profile
Name
Niagen Bioscience Inc
Sector
Industry
Phone
310-388-6706
Address
10900 WILSHIRE BLVD, LOS ANGELES
Compare NAGE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NAGE
Niagen Bioscience Inc
|
7.48 | 602.93M | 116.30M | 17.73M | 20.88M | 0.21 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Niagen Bioscience Inc Stock (NAGE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-27-25 | Initiated | Canaccord Genuity | Buy |
| Aug-16-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-11-22 | Downgrade | B. Riley Securities | Buy → Neutral |
| Mar-08-22 | Initiated | ROTH Capital | Buy |
| Oct-16-19 | Initiated | Oppenheimer | Outperform |
| Feb-14-19 | Initiated | B. Riley FBR | Buy |
| Nov-27-17 | Resumed | H.C. Wainwright | Buy |
| Sep-25-17 | Initiated | Ladenburg Thalmann | Buy |
| Jan-03-17 | Initiated | Rodman & Renshaw | Buy |
View All
Niagen Bioscience Inc Stock (NAGE) Latest News
Is Niagen Bioscience Inc. a candidate for recovery playJuly 2025 Review & Fast Gaining Stock Reports - newser.com
How Niagen Bioscience Inc. (OCD1) stock trades pre earnings2025 Stock Rankings & Community Consensus Stock Picks - newser.com
What earnings revisions data tells us about Niagen Bioscience Inc.2025 Market Overview & Expert Curated Trade Ideas - newser.com
Niagen Bioscience's (NAGE) Hold (C) Rating Reiterated at Weiss Ratings - MarketBeat
Tools to assess Niagen Bioscience Inc.’s risk profileJuly 2025 Breakouts & Expert Approved Momentum Trade Ideas - newser.com
Owning 37% shares,institutional owners seem interested in Niagen Bioscience, Inc. (NASDAQ:NAGE), - Yahoo Finance
What is Roth Capital’s Estimate for NAGE Q3 Earnings? - Defense World
When is the best time to exit Niagen Bioscience Inc.Global Markets & Risk Controlled Daily Plans - newser.com
Pattern recognition hints at Niagen Bioscience Inc. upsideJuly 2025 Market Mood & Safe Swing Trade Setups - newser.com
Will Niagen Bioscience Inc. stock go up soonTrade Risk Assessment & Accurate Technical Buy Alerts - newser.com
Full technical analysis of Niagen Bioscience Inc. stockShare Buyback & Capital Protection Trading Alerts - newser.com
Niagen Bioscience raises 2025 sales outlook on NAD+ market growth By Investing.com - Investing.com Nigeria
Niagen Bioscience Raises 2025 Sales Outlook Amid FDA Ruling - TipRanks
Niagen Bioscience, Inc. Provides Net Sales Guidance for the Full-Year 2025 - MarketScreener
Niagen Bioscience (NAGE) Gains Attention with FDA's NMN Ruling R - GuruFocus
Niagen Bioscience (NAGE) Boosts 2025 Sales Forecast - GuruFocus
Niagen Bioscience increases full year 2025 net sales outlook to 25% to 30% year-over-year growth - MarketScreener
Niagen Bioscience raises 2025 sales outlook on NAD+ market growth - Investing.com
Niagen Bioscience Increases Full Year 2025 Net Sales Outlook to 25% to 30% Year-Over-Year Growth - Business Wire
What margin trends mean for Niagen Bioscience Inc. stockEarnings Beat & Technical Buy Zone Confirmation - newser.com
Is Niagen Bioscience Inc. reversing from oversold territoryJuly 2025 Selloffs & Trade Opportunity Analysis Reports - newser.com
Roth Capital Issues Pessimistic Estimate for NAGE Earnings - Defense World
A Fresh Look at Niagen Bioscience (NAGE) Valuation After Nationwide iCRYO Distribution Expansion - Sahm
Roth Capital Lowers Earnings Estimates for Niagen Bioscience - MarketBeat
Niagen Bioscience, Inc.'s (NASDAQ:NAGE) 25% Cheaper Price Remains In Tune With Revenues - simplywall.st
Niagen Bioscience, Inc.'s (NASDAQ:NAGE) Stock Retreats 25% But Revenues Haven't Escaped The Attention Of Investors - 富途牛牛
What macro factors could drive Niagen Bioscience Inc. (OCD1) stock higher2025 Market WrapUp & Precise Buy Zone Identification - newser.com
Niagen Bioscience's Pharmaceutical-Grade Niagen IV and Injections Now Available at over 50 iCRYO Clinics and More than 900 Total Clinics Nationwide - MarketScreener
Niagen IV now available at over 900 clinics nationwide By Investing.com - Investing.com Canada
Niagen Bioscience (NAGE) Expands Product Reach to Over 900 U.S. Clinics - GuruFocus
Niagen IV now available at over 900 clinics nationwide - Investing.com India
Niagen Bioscience's Pharmaceutical-Grade Niagen™ IV and Injections Now Available at over 50 iCRYO Clinics and More than 900 Total Clinics Nationwide - Yahoo Finance
Analyzing Niagen Bioscience (NASDAQ:NAGE) and CureVac (NASDAQ:CVAC) - Defense World
Niagen Bioscience (NASDAQ:NAGE) Trading Down 6.4%What's Next? - MarketBeat
Brokerages Set Niagen Bioscience, Inc. (NASDAQ:NAGE) Price Target at $13.42 - Defense World
Niagen Bioscience Inc Stock (NAGE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Niagen Bioscience Inc Stock (NAGE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Lopez Carlos Luis | SVP, General Counsel |
Mar 07 '25 |
Buy |
7.86 |
273 |
2,146 |
2,251 |
| Jaksch Frank L Jr | Director |
Dec 13 '24 |
Option Exercise |
3.66 |
50,001 |
183,004 |
281,340 |
| Jaksch Frank L Jr | Director |
Dec 13 '24 |
Sale |
6.19 |
37,161 |
229,956 |
244,179 |
5.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):